Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $950.00 Price Target at JPMorgan Chase & Co.

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price raised by JPMorgan Chase & Co. from $850.00 to $950.00 in a report issued on Monday morning,Benzinga reports. The firm currently has an overweight rating on the biopharmaceutical company’s stock.

A number of other equities analysts also recently commented on the stock. BMO Capital Markets upped their target price on shares of Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the stock an “outperform” rating in a research note on Thursday, December 4th. Oppenheimer restated an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a report on Monday. Canaccord Genuity Group lifted their target price on Regeneron Pharmaceuticals from $850.00 to $1,057.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. Wall Street Zen downgraded Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Finally, Citigroup lifted their price objective on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Three analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $799.74.

Regeneron Pharmaceuticals Price Performance

REGN opened at $755.02 on Monday. The business has a fifty day moving average of $758.27 and a 200 day moving average of $652.73. The stock has a market cap of $79.35 billion, a P/E ratio of 18.17, a PEG ratio of 1.92 and a beta of 0.40. The company has a quick ratio of 4.22, a current ratio of 4.77 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 52-week low of $476.49 and a 52-week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, topping the consensus estimate of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The business’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period last year, the company earned $12.07 earnings per share. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be issued a $0.94 dividend. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date is Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.47%.

Insider Activity

In other news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total value of $1,200,000.00. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 46.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $651.43, for a total transaction of $280,766.33. Following the sale, the vice president directly owned 4,233 shares of the company’s stock, valued at $2,757,503.19. The trade was a 9.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 7.02% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. WPG Advisers LLC increased its holdings in shares of Regeneron Pharmaceuticals by 312.5% during the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 25 shares in the last quarter. Board of the Pension Protection Fund purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $31,000. Salomon & Ludwin LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $27,000. Torren Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $38,000. Finally, FNY Investment Advisers LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $38,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals News Summary

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: JPMorgan sharply raised its price target to $950 and moved to “overweight,” signaling a sizable upside thesis tied to Regeneron’s recent results and trajectory. Benzinga
• Positive Sentiment: Oppenheimer reaffirmed “outperform” and lifted its target to $865, showing dealer conviction that Q4 results justify higher analyst estimates. Benzinga
• Positive Sentiment: Cantor Fitzgerald and Wells Fargo raised targets (to $800), with Cantor keeping an “overweight” view — reinforcing industrywide upgrades following the quarter. Benzinga
• Positive Sentiment: Regeneron highlighted EYLEA HD Phase 3 presentations at Angiogenesis 2026 (final 64‑week QUASAR and full ELARA results), which support the drug’s clinical profile and could underpin retinal franchise growth. EYLEA HD Presentations
• Positive Sentiment: Investors are digesting the company’s upbeat Q4 report (EPS and revenue beats) and accompanying earnings call commentary that boosted near‑term visibility. Q4 Earnings Transcript
• Neutral Sentiment: Morgan Stanley nudged its target to $769 but kept an “equal weight” rating — a modest adjustment that suggests limited conviction for sizable near‑term upside. TickerReport
• Neutral Sentiment: Truist trimmed its target slightly (to $818) but maintained a “buy,” reflecting minor calibration rather than a change in long‑term view. TickerReport
• Neutral Sentiment: Market commentary and pieces on Regeneron’s pipeline vs. valuation highlight a valuation gap and focus investors on execution of key pipeline catalysts over the next 12–24 months. Yahoo Finance

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.